GC Cell said Thursday that it has signed a co-development agreement with Lunit, a medical AI company, for AB-201, GC Cell's allogeneic chimeric antigen receptor-natural killer (CAR-NK) cell therapy targeting solid tumors.
Under this accord, GC Cell will conduct a phase 1 study of AB-201 by utilizing Lunit's AI biomarker, Lunit SCOPE IO, which Lunit is developing.
While immunohistochemistry (IHC) staining, one of the commonly used tests for biomarker identification, is based on human judgment, the research technique using Lunit SCOPE IO, an AI pathology analysis technology platform, has the advantage of studying more advanced human epithelial growth factor receptor type 2 (HER2) expression through quantified data.
AB-201 is an off-the-shelf (OTS), cryopreserved, allogeneic CAR-NK cell therapy consisting of cord blood-derived NK cells loaded with a CAR that targets HER2, which is overexpressed in breast, ovarian, and gastric cancers.
Please click on Reference link below if you wish to read the full article.